GlaxoSmithKline Upgraded by S&P Equity Research to Hold (GSK)
GlaxoSmithKline (NYSE:GSK) was upgraded by equities researchers at S&P Equity Research from a “sell” rating to a “hold” rating in a research report issued on Monday, AR Network reports.
A number of other analysts have also recently weighed in on GSK. Analysts at Berenberg Bank downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note to investors on Friday. Separately, analysts at Cowen and Company downgraded shares of GlaxoSmithKline from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday, January 22nd. They now have a $57.00 price target on the stock. Finally, analysts at UBS AG initiated coverage on shares of GlaxoSmithKline in a research note to investors on Thursday, January 9th. They set a “neutral” rating on the stock. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $88.33.
GlaxoSmithKline (NYSE:GSK) traded up 0.24% during mid-day trading on Monday, hitting $53.46. The stock had a trading volume of 1,008,278 shares. GlaxoSmithKline has a one year low of $43.68 and a one year high of $55.07. The stock’s 50-day moving average is $52.64 and its 200-day moving average is $51.90. The company has a market cap of $128.8 billion and a P/E ratio of 21.03.
GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.